We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. November 20 marks World COPD Day 2024, a worldwide ...
We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...
AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...
GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...
Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
Mona Bafadhel receives funding from the National Institute of Health Research, Asthma+Lung UK, and Horizon Europe. For this study, Mona Bafadhel received funding from AstraZeneca to complete the study ...
AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...
Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback